Comparative Pharmacology
Head-to-head clinical analysis: TRI LEGEST FE versus TRIPHASIL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LEGEST FE versus TRIPHASIL 28.
TRI-LEGEST FE vs TRIPHASIL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tri-Legest FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It prevents ovulation by inhibiting gonadotropin release (FSH and LH) and alters cervical mucus and endometrial lining to impede sperm penetration and implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropin secretion, inhibits ovulation, alters cervical mucus and endometrium.
One tablet orally once daily for 28-day cycle: 21 days active tablets (norethindrone/ethinyl estradiol) followed by 7 days placebo. For contraception only.
1 tablet orally once daily for 28 days; each tablet contains levonorgestrel 0.050 mg and ethinyl estradiol 0.030 mg (6 days), levonorgestrel 0.075 mg and ethinyl estradiol 0.040 mg (5 days), levonorgestrel 0.125 mg and ethinyl estradiol 0.030 mg (10 days), followed by 7 inert tablets. The first dose is taken on the first Sunday after onset of menstruation or on day 1 of the menstrual cycle.
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 18 hours (terminal). Steady-state reached after 7 days; clinical contraceptive efficacy requires consistent dosing.
Levonorgestrel: terminal half-life 11-45 hours (mean 24-30 h); Ethinyl estradiol: terminal half-life 10-27 hours (mean 17 h). Steady-state reached after 5-7 days.
Renal: ~60% (metabolites), Fecal: ~30% (metabolites), Biliary: minor (~5% as conjugates)
Renal (about 50-60% as metabolites, <10% unchanged), fecal (about 30-40% via biliary elimination). Ethinyl estradiol undergoes enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive